<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4761">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01773902</url>
  </required_header>
  <id_info>
    <org_study_id>PfP3.2</org_study_id>
    <nct_id>NCT01773902</nct_id>
  </id_info>
  <brief_title>Protein for Premies</brief_title>
  <official_title>High Versus Standard Dose Protein for Very Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although expressed breast milk is considered the optimal nutritional source for preterm
      infants, the macronutrient content is insufficient to enable optimal growth  during neonatal
      intensive care. Optimal dose and optimal mode of administration (standardized or
      individualized) of enteral protein supplementation to very preterm infants have not been
      established.

      This study aims to compare the effects on weight gain of different modes of enteral protein
      supplementation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Weight gain</measure>
    <time_frame>From birth - to the end of study intervention (anticipated to be on average 1 week before discharge home at approx 37 weeks PMA)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Head circumference growth</measure>
    <time_frame>From birth - to the end of study intervention (anticipated to be on average 1 week before discharge home at approx 37 weeks PMA)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma amino acid profile</measure>
    <time_frame>at 2 and 4 weeks after start of intervention</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Extreme Prematurity</condition>
  <arm_group>
    <arm_group_label>High Dose Protein (Individualized)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if &lt;1500g b.w. or 4.0g/kg/d of enteral protein if &gt;1500g b.w. until 1 week before discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Protein (Standardized)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard protein supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Protein supplementation independent of individual breast milk content using a standard dose of a standard breast milk fortifier until 1 week before discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High Dose Protein (Individualized)</intervention_name>
    <description>Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if &lt;1500g b.w. or 4.0g/kg/d of enteral protein if &gt;1500g b.w. until 1 week before discharge</description>
    <arm_group_label>High Dose Protein (Individualized)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High Dose Protein (Standardized)</intervention_name>
    <description>Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge</description>
    <arm_group_label>High Dose Protein (Standardized)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standard Protein Supplementation</intervention_name>
    <description>Protein supplementation independent of individual breast milk content using a standard-dose-protein breast milk fortifier until 1 week before discharge</description>
    <arm_group_label>Standard protein supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  very preterm infants &lt;32 weeks gestation and &lt;1500g birth weight

          -  &gt; 100ml/kg/d of enteral feeding

        Exclusion Criteria:

          -  missing informed consent

          -  decision not to feed breast milk

          -  congenital malformations

          -  age &gt; 7 days at study entry
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Franz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tuebingen, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Axel Franz, MD</last_name>
    <email>axel.franz@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Children's Hospital Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Franz, MD</last_name>
      <email>axel.franz@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Maas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 20, 2013</lastchanged_date>
  <firstreceived_date>January 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Axel Franz</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
